- Home
- PRCH vs ADCT Comparison
PRCH vs ADCT Comparison
Compare PRCH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCH
- ADCT
- Stock Information
- Founded
- PRCH 2012
- ADCT 2011
- Country
- PRCH United States
- ADCT Switzerland
- Employees
- PRCH N/A
- ADCT N/A
- Industry
- PRCH Computer Software: Prepackaged Software
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PRCH Technology
- ADCT Health Care
- Exchange
- PRCH Nasdaq
- ADCT Nasdaq
- Market Cap
- PRCH 656.3M
- ADCT 241.0M
- IPO Year
- PRCH N/A
- ADCT 2020
- Fundamental
- Price
- PRCH $12.20
- ADCT $2.68
- Analyst Decision
- PRCH Strong Buy
- ADCT Strong Buy
- Analyst Count
- PRCH 8
- ADCT 6
- Target Price
- PRCH $9.66
- ADCT $7.80
- AVG Volume (30 Days)
- PRCH 2.2M
- ADCT 947.2K
- Earning Date
- PRCH 08-05-2025
- ADCT 08-05-2025
- Dividend Yield
- PRCH N/A
- ADCT N/A
- EPS Growth
- PRCH N/A
- ADCT N/A
- EPS
- PRCH N/A
- ADCT N/A
- Revenue
- PRCH $427,150,000.00
- ADCT $75,817,000.00
- Revenue This Year
- PRCH $4.28
- ADCT $10.65
- Revenue Next Year
- PRCH $12.88
- ADCT $15.05
- P/E Ratio
- PRCH N/A
- ADCT N/A
- Revenue Growth
- PRCH N/A
- ADCT 10.49
- 52 Week Low
- PRCH $1.05
- ADCT $1.05
- 52 Week High
- PRCH $12.83
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- PRCH 67.10
- ADCT 44.48
- Support Level
- PRCH $10.55
- ADCT $2.59
- Resistance Level
- PRCH $12.09
- ADCT $2.98
- Average True Range (ATR)
- PRCH 0.71
- ADCT 0.29
- MACD
- PRCH 0.04
- ADCT -0.13
- Stochastic Oscillator
- PRCH 84.77
- ADCT 5.63
About PRCH Porch Group Inc.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).